Dr Reddy’s inks deal to bring ‘affordable’ CAR-T therapy to India biopharma-reporter.com
Simple understanding of CAR-T Therapy
Another simple diagram to understand CAR-T cell therapy
Another Diagram to understand CAR-T therapy
The first step in the production of CAR-T cells is the isolation of T cells from human blood. CAR-T cells may be manufactured either from the patient's own blood, known as an autologous treatment, or from the blood of a healthy donor, known as an allogeneic treatment.
First, leukocytes are isolated using a blood cell separator in a process known as leukocyte apheresis. Peripheral blood mononuclear cells (PBMC) are then separated and collected.The products of leukocyte apheresis are then transferred to a cell-processing center.
The products of leukocyte apheresis are then transferred to a cell-processing center. In the cell processing center, specific T cells are stimulated so that they will actively proliferate and expand to large numbers.
The expanded T cells are purified and then transduced with a gene encoding the engineered CAR via a retroviral vector, typically either an integrating gammaretrovirus (RV) or a lentiviral (LV) vector.
T cells are genetically engineered to express chimeric antigen receptors specifically directed toward antigens on a patient's tumor cells, then infused into the patient where they attack and kill the cancer cells.
FDA approved CART therapy
CAR-T therapy - concall of Dr Reddys
Loading suggestions...